Allianz Asset Management GmbH Purchases 43,600 Shares of Envista Holdings Corporation $NVST

Allianz Asset Management GmbH lifted its position in Envista Holdings Corporation (NYSE:NVST) by 10.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 469,085 shares of the company’s stock after purchasing an additional 43,600 shares during the quarter. Allianz Asset Management GmbH’s holdings in Envista were worth $9,166,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in NVST. Parallel Advisors LLC increased its holdings in shares of Envista by 100.1% in the second quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock worth $55,000 after purchasing an additional 1,397 shares during the last quarter. FourThought Financial Partners LLC bought a new stake in shares of Envista in the first quarter worth about $180,000. Vestcor Inc bought a new stake in shares of Envista in the first quarter worth about $211,000. Aigen Investment Management LP bought a new stake in shares of Envista in the first quarter worth about $274,000. Finally, State of Wyoming increased its holdings in shares of Envista by 121.1% in the first quarter. State of Wyoming now owns 16,911 shares of the company’s stock worth $292,000 after purchasing an additional 9,264 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts recently commented on NVST shares. Stifel Nicolaus lifted their price target on Envista from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Evercore ISI set a $25.00 price target on Envista in a research report on Wednesday, October 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Envista in a research report on Wednesday, October 8th. Mizuho lifted their price target on Envista from $15.00 to $18.00 and gave the stock an “underperform” rating in a research report on Friday, August 1st. Finally, Piper Sandler lifted their price target on Envista from $17.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $21.08.

Envista Stock Down 0.4%

Shares of NYSE:NVST opened at $20.07 on Wednesday. Envista Holdings Corporation has a 1 year low of $14.22 and a 1 year high of $23.00. The business has a 50 day simple moving average of $20.64 and a two-hundred day simple moving average of $19.11. The firm has a market capitalization of $3.33 billion, a PE ratio of 62.71, a price-to-earnings-growth ratio of 1.08 and a beta of 1.01. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.44 and a quick ratio of 2.08.

Envista (NYSE:NVST) last announced its earnings results on Thursday, July 31st. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.02. Envista had a return on equity of 4.84% and a net margin of 2.11%.The business had revenue of $682.10 million during the quarter, compared to analyst estimates of $638.21 million. During the same quarter in the previous year, the business earned $0.11 earnings per share. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. Envista has set its FY 2025 guidance at 1.050-1.15 EPS. On average, equities analysts predict that Envista Holdings Corporation will post 1 EPS for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.